A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
A phase 3 trial of Pucotenlimab, run by Taizhou Hanzhong biomedical co. LTD in colorectal cancer, active.
Overview
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05652894 by Taizhou Hanzhong biomedical co. LTD, with 190 participants planned, started 2023-02-28. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomized Phase III Study of HX008 (a Humanized Monoclonal Antibody Against PD-1) Compared to Investigator's Choice Chemotherapy in the First-Line Treatment of Subjects With Microsatellite Instability-High (MSI-H)/Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Phase
Phase 3
Sponsor
Taizhou Hanzhong biomedical co. LTD
Registry
Enrolled
190